Conrado Roberto Hoffmann Filho

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 3 drugs with upcoming expirations

Activity

Key Events

Oct 7, 2026FDAAccutane — ZENATANE

Aug 21, 2026FDAAccutane — ZENATANE

Feb 9, 2026FDAAccutane — ZENATANE

Mar 24, 2023FDAAccutane — ZENATANE

Mar 17, 2023TrialEvaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department

Oct 6, 2022FDAAccutane — ZENATANE

Aug 23, 2022FDAAccutane — ZENATANE

Aug 8, 2022FDAVersed — MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)

1 more events

Aug 8, 2022FDAVersed — MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

7 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Zelboraf3 patentsJun 21, 2026 Versed4 patentsJan 18, 2028 ZelborafJun 20, 2029 ZelborafJul 27, 2030 ZelborafJun 6, 2032 Accutane2 patentsMay 29, 2035 VersedJun 20, 2038

Regulatory

Regulatory Timeline

20192 events

FDANov 5

Accutane — ABSORICA LD

Application NDA211913 (NDA)

FDAAug 2

Tamiflu — TAMIFLU

Application NDA021246

20202 events

FDADec 9

Accutane — ZENATANE

Application ANDA202099

FDANov 16

Accutane — ZENATANE

Application ANDA202099

20215 events

FDANov 9

Accutane — ZENATANE

Application ANDA202099

FDAOct 8

Accutane — ZENATANE

Application ANDA202099

FDAAug 10

Tamiflu — TAMIFLU

Application NDA021246

FDAMar 22

Versed — MIDAZOLAM IN 0.9% SODIUM CHLORIDE

Application NDA211844 (NDA)

FDAMar 22

Versed — MIDAZOLAM IN 0.9% SODIUM CHLORIDE

Application NDA211844 (NDA)

20227 events

FDAOct 6

Accutane — ZENATANE

Application ANDA202099

FDAAug 23

Accutane — ZENATANE

Application ANDA202099

FDAAug 8

Versed — MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)

Application NDA216359 (NDA)

FDAAug 8

Versed — MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)

Application NDA216359 (NDA)

FDAAug 4

Accutane — ZENATANE

Application ANDA202099

FDAJul 20

Versed — MIDAZOLAM IN 0.8% SODIUM CHLORIDE

Application NDA215868 (NDA)

FDAJul 20

Versed — MIDAZOLAM IN 0.8% SODIUM CHLORIDE

Application NDA215868 (NDA)

20231 event

FDAMar 24

Accutane — ZENATANE

Application ANDA202099

20263 events

FDAOct 7

Accutane — ZENATANE

Application ANDA202099

FDAAug 21

Accutane — ZENATANE

Application ANDA202099

FDAFeb 9

Accutane — ZENATANE

Application ANDA202099

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)